South Korean AI firm Lunit has tied up with its investor, Guardant Well being, for AI integration.
Beneath the partnership, Lunit will combine its PD-L1 scoring algorithm into Guardant’s most cancers biomarker detection workflow within the Guardant360 TissueNextTM PD-L1 check for non-small cell lung most cancers (NSCLC).
Lunit SCOPE PD-L1, a CE-marked AI answer, detects and analyses PD-L1, a sort of most cancers biomarker.Â
WHY IT MATTERS
The Lunit SCOPE PD-L1 does AI-based quantification of tissue samples utilizing a scoring system. Integrating it with the Guardant check will improve biomarker evaluation for NSCLC sufferers, the corporate claimed in a press assertion. The AI has helped raise the check’s detection of PD-L1 by over 20% in comparison with guide pathologist interpretation.Â
THE LARGER TREND
In 2021, Guardant Well being backed Lunit’s Sequence C Tranche B funding spherical with a $26 million funding. The corporate beforehand mentioned that it expects its funding within the firm for use in growing new precision oncology merchandise that enhance most cancers care.
On Thursday, Guardant Well being formally launched Guardant Galaxy, its suite of analytical applied sciences developed internally and thru outdoors partnerships. The Guardant360 TissueNext PD-L1 check built-in with Lunit SCOPE PD-L1 is the primary utility on this line.Â
In different associated information, Lunit opened the brand new yr with a three-year deal to provide its AI chest x-ray picture evaluation software program, Lunit INSIGHT CXR, to Hospital Israelita Albert Einstein, one of many largest hospitals in Brazil.
ON THE RECORD
“The digital pathology answer from Lunit has already demonstrated the ability of AI to assist enhance [the] detection of PD-L1 in sure instances of NSCLC. We imagine it has the potential to contribute far more broadly to advances in figuring out most cancers biomarkers and informing therapy selections,” Guardant Well being co-CEO Helmy Eltoukhy mentioned about Lunit’s AI answer.
“The event of the AI-supported scoring algorithm for the Guardant360 TissueNext PD-L1 check is a superb instance of utilizing superior medical picture analytics to reinforce precision diagnostics in lung most cancers and assist medical doctors discover the fitting therapy for the fitting sufferers,” Lunit CEO Brandon Suh additionally commented.
